June 11, 2020 / 12:44 PM / a month ago

BRIEF-Exelixis Inc - Initiation Follows Positive Results From Cohort 7 Of Phase 1B Cosmic-021 Trial

Exelixis Inc:

* EXELIXIS ANNOUNCES INITIATION OF CONTACT-01 PHASE 3 PIVOTAL TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PREVIOUSLY TREATED METASTATIC NON-SMALL CELL LUNG CANCER

* EXELIXIS INC - INITIATION FOLLOWS POSITIVE RESULTS FROM COHORT 7 OF PHASE 1B COSMIC-021 TRIAL

* EXELIXIS INC - CONTACT-01 IS FIRST OF THREE PHASE 3 PIVOTAL TRIALS THAT ARE PART OF A PREVIOUSLY ANNOUNCED CLINICAL COLLABORATION WITH ROCHE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below